Latest From HOPA

An image of pancreatic cancer
HOPA News Late Breaking News

Late-Breaking HOPA News: RASolute 302 Breakthrough in Metastatic Pancreatic Adenocarcinoma

Michael Arnold, PharmD, discusses the very encouraging results from the RASolute 302 trial, a potential breakthrough in pancreatic cancer threapy.

Blood stem cells
HOPA News Late Breaking News

Late-Breaking HOPA News: Precision-T: Orca-T and the Evolution of GVHD Prophylaxis in Allogeneic Transplantation

Nathan Schieldt, PharmD, BCOP, discusses allogeneic hematopoietic stem cell transplantation's place as a potentially curative therapy for high-risk hematologic malignancies and how Orca-T provides a novel approach to allo-HSCT.

Lungs with cancer
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Amivantamab and Hyaluronidase-lpuj

Mealis Taouk, PharmD, PGY2 Oncology Pharmacy Resident, and Karen Abboud, PharmD, BCPS, BCOP - both from Houston Methodist Hospital in Houston, TX - write about amivantamab and hyaluronidase-lpuj (Rybrevant Faspro).

An image of lungs against the outline of a body
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Sevabertinib

Yasmin Nasser, PharmD, PGY1 Pharmacy Resident, and Kiera Roubal, PharmD, BCOP, Oncology Clinical Pharmacist, discuss the role of sevabertinib in the treatment of non-squamous non-small cell lung cancer.

Advocacy

End Cancer Drug Shortages Coalition: A Consensus Statement on Drug Shortages

HOPA has spearheaded a multi-year initiative with 16 other organizations to establish the consensus for combating cancer drug shortages. The statement outlines the major factors contributing to this crisis, and recommends policy solutions.

A group of HOPA Annual Conference 2026 attendees gathered around a colorful HOPA sign
Membership

The Good Times Rolled at Record-Breaking HOPA Annual Conference 2026

Hosted in New Orleans, the 2026 edition of HOPA's annual gathering totaled 1,785 registrants, topping the event's previous high set just last year.

HOPA logo
Advocacy

HOPA Issues Updated Drug Shortages Brief

Shortages of drugs that are essential for the treatment and care of individuals with cancer result in compromises to patient care and, ultimately, outcomes.

An oncology pharmacist helping a patient
Advocacy

Oncology Pharmacist Survey: Understanding Task Value and Professional Satisfaction

Recent publications have explored workload and productivity to improve oncology pharmacy practice. HOPA aimed to build upon that research by assessing task valuation.

Oncology Pharmacist Day image
Membership

Oncology Pharmacist Day: Celebrating the People Who Make the Profession

On April 3, 2026, the oncology pharmacy community will mark the first-ever Oncology Pharmacist Day, a new annual observance recognizing the essential role hematology/oncology pharmacists play in improving the lives of people affected by cancer.

An image of multiple myeloma cells
HOPA News Late Breaking News

Late-Breaking HOPA News: Redefining Relapse: What MajesTEC-3 Means for the Treatment of Multiple Myeloma

Sanja Zepcan, PharmD, BCPS, BCOP, and Emily Rux, PharmD, BCOP, discuss the clinical questions raised by the recent MajesTEC-3 trial and the potential changes it finds in the treatment of multiple myeloma.

An image of chronic lymphocytic leukemia cells under a microscope
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Pirtobrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Cristina V. Martinez, PharmD, PGY2 Oncology Pharmacy Resident, and Hunter Sowell, PharmD, BCOP, Clinical Pharmacy Specialist Oncology, analyze the potential role for pirtobrutinib in treating chronic lymphocytic leukemia and small lymphocytic lymphoma.

A photo of three pharamcists smiling
Collaborations

Pharmacy Students and Oncology Pharmacists Combat Cancer Misinformation with National Initiative

The Hematology/Oncology Pharmacy Association (HOPA) is proud to team up with the Student National Pharmaceutical Association (SNPhA) for the Cancer Clarity Challenge, a new national competition.